LEADER 00916nam0-2200313---450- 001 990008252390403321 005 20060110122510.0 010 $a0-582-23852-8 035 $a000825239 035 $aFED01000825239 035 $a(Aleph)000825239FED01 035 $a000825239 100 $a20060110d2000----km-y0itay50------ba 101 0 $aeng 102 $aGB 105 $ay-------001yy 200 1 $aBritain in the age of the French revolution 1785-1820$fJennifer Mori 210 $aHarlow$cPearson education$d2000 215 $aX, 259 p.$d24 cm 610 0 $aGran Bretagna$aPolitica e governo$a1789-1820 676 $a941.073$v21$zita 700 1$aMori,$bJennifer$0499414 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990008252390403321 952 $aXIV A 705$b37342$fFSPBC 959 $aFSPBC 996 $aBritain in the age of the French revolution 1785-1820$9743024 997 $aUNINA LEADER 01067nam a2200301 i 4500 001 991001288189707536 005 20020507190706.0 008 931204s1988 uk ||| | eng 020 $a0127329609 035 $ab10826683-39ule_inst 035 $aLE01309971$9ExL 040 $aDip.to Matematica$beng 082 0 $a512.55 084 $aAMS 20C 084 $aQA3.P8 100 1 $aWallach, Nolan R.$041086 245 10$aReal reductive groups I /$cNolan R. Wallach 260 $aNew York ; London :$bAcademic press,$c1988 300 $axix, 412 p. ;$c23 cm. 490 0 $aPure and applied mathematics.$pA series of monographs & textbooks [Academic Press],$x0079-8169 ;$v132 650 4$aLie groups 650 4$aRepresentations of groups 907 $a.b10826683$b23-02-17$c28-06-02 912 $a991001288189707536 945 $aLE013 20C WAL11 (1988)$g1$i2013000075174$lle013$o-$pE0.00$q-$rl$s- $t0$u0$v0$w0$x0$y.i10934650$z28-06-02 996 $aReal Reductive Groups I$9382801 997 $aUNISALENTO 998 $ale013$b01-01-93$cm$da $e-$feng$guk $h0$i1 LEADER 04733nam 2200745 450 001 9910821774103321 005 20221212045028.0 010 $a1-4875-3799-9 010 $a1-4875-3798-0 024 7 $a10.3138/9781487537982 035 $a(CKB)4100000011476387 035 $a(MiAaPQ)EBC6358308 035 $a(DE-B1597)570807 035 $a(DE-B1597)9781487537982 035 $a(OCoLC)1202479544 035 $a(MdBmJHUP)musev2_108979 035 $a(EXLCZ)994100000011476387 100 $a20210225d2020 uy 0 101 0 $aeng 135 $aur||||||||||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aIn sight $emy life in science and biotech /$fJulia Levy, Molly Shoichet 210 1$aToronto, Ontario, Canada ;$aBuffalo, New York ;$aLondon, England :$cUniversity of Toronto Press,$d[2020] 210 4$dİ2020 215 $a1 online resource (312 p.) 300 $aIncludes index. 311 $a1-4875-0831-X 327 $tFrontmatter -- $tContents -- $tForeword -- $t1 Waiting for the Other Shoe to Drop -- $t2 Does Your Dog Always Sit in the Front Seat? -- $t3 Where I Wanted to Be -- $t4 Life in Bed-Sits -- $t5 Woefully Outclassed -- $t6 Whose Lab Do You Work in? -- $t7 Earning My Stripes -- $t8 Seeing the Light -- $t9 Becoming Part of a Biotech Start-Up -- $t10 Positioning QLT as a Photodynamic Therapy Company -- $t11 Colleagues at American Cyanamid Come to Our Rescue -- $t12 The Nation?s Blood Supply -- $t13 PDT Is Different from Other Cancer Drugs -- $t14 I Was Surprised and Not at All Pleased -- $t15 Splitting Up -- $t16 Failure Was Never an Option -- $t17 Nothing Can Prepare You for the Torture of ODAC -- $t18 Taking Big Steps in Our AMD Clinical Trials -- $t19 An Open and Respectful Relationship -- $t20 Our Work on Age-Related Macular Degeneration Is Her Legacy -- $t21 We at QLT Were on Pins and Needles -- $t22 People Couldn?t Stop Smiling -- $t23 More Than a One-Trick Pony -- $t24 Launching the Product and Hoping for No Unpleasant Surprises -- $t25 Growing the Company -- $t26 Time to Reflect -- $t27 An Enormous Rush of Relief -- $t28 A Biotech Company with a Lot of Money Is in Danger -- $t29 I Thought These Problems Would Be Transient -- $t30 Ongoing Headaches -- $t31 He Felt Thoroughly Betrayed -- $t32 Problems with Activist Shareholders -- $t33 New Opportunity -- $tAcknowledgments -- $tAbout the Author -- $tIndex 330 $a"In Sight is a memoir about how a love of science and discovery drove Julia Levy, a celebrated scholar and biotech CEO, to work her way through gender bias in order to achieve academic and professional recognition. Her story traces the unconventional invention of a breakthrough drug treatment from its development from laboratory researchin the laboratory to its application as a medical treatment for vision loss. Told from a female perspective, In Sight is a unique and personal story covering Levy's early years as a refugee, her university training in the UK, and her appointment as professor at the University of British Columbia. Years spent as an academic led gave the author to unexpected exposure to the biotechnology industry and a chance meeting with colleagues that led to the formation of a lucrative biotechnology company, known today as QLT Inc. The bulk of the book covers the years spent building the company, and Levy's surprising transition from chief scientific officer to CEO. In Sight is an honest description of the trials of drug development, the tensions inherent in the commercialization of health innovations, and the truly remarkable hurdles faced by women in the scientific community."--$cProvided by publisher. 606 $aMicrobiologists$zCanada$vBiography 606 $aCollege teachers$zCanada$vBiography 607 $aCanada$2fast 607 $aCanada 608 $aAutobiographies.$2fast 608 $aBiographies.$2fast 608 $aAutobiographies.$2lcgft 610 $aIPO. 610 $aQLT. 610 $aSTEM. 610 $aVisudyne. 610 $abiography. 610 $abiotechnology. 610 $acareers. 610 $acommercialisation of science. 610 $amacular degeneration. 610 $amemoir. 610 $aphotodynamic. 610 $atherapy. 610 $awomen in business. 610 $awomen in science. 615 0$aMicrobiologists 615 0$aCollege teachers 676 $a579.092 686 $acci1icc$2lacc 700 $aLevy$b Julia G.$f1934-$01540851 702 $aShoichet$b Molly 801 0$bMiAaPQ 801 1$bMiAaPQ 801 2$bMiAaPQ 906 $aBOOK 912 $a9910821774103321 996 $aIn sight$93986784 997 $aUNINA LEADER 00778nam0-22002771i-450 001 990002041560403321 005 20241217131500.0 035 $a000204156 100 $a20030910d1882----km-y0itay50------ba 101 0 $afre 102 $aFR 105 $aa m001yy 200 1 $a<>olivier$eson histoire, sa culture, ses ennemis, ses maladies et ses amis$fA. Peragallo 205 $a2e ed. 210 $aNice$cTyp. S. Cauvin-Empereur$d1882 215 $a180 p., 1 tv.$d25 cm 610 0 $aImenotteri$aVespidae 676 $a595.79$v23$zita 700 1$aPeragallo,$bA.$0358786 801 0$aIT$bUNINA$gRICA$2UNIMARC 901 $aBK 912 $a990002041560403321 952 $aB ENT 88$b01/0088/25$fFAGBC 959 $aFAGBC 996 $aOlivier$9407020 997 $aUNINA